Pre-clinical biopharma developing next-generation multimeric siRNA and ASO therapeutics targeting neurodegenerative diseases. Proprietary FORGE platform uses cross-species screening to design dimer/trimer/tetramer constructs with tunable linkers and novel conjugates for superior CNS distribution, durable multi-gene modulation, and precise combinatorial polypharmacology.